Views Article – Sharenet Wealth

News, North America

S.Africa’s Biovac to start making Pfizer-BioNTech vaccine in H2 2022 – CEO

CAPE TOWN, July 21 (Reuters) – South Africa’s Biovac Institute is aiming to start production of the mRNA COVID-19 vaccine developed by Pfizer and BioNTech in the second half of next year, its chief executive officer said on Wednesday.

Morena Makhoana told Reuters the Cape Town-based firm would ramp up production of the COVID-19 vaccine before reaching output of 100 million doses a year around early 2023. (Reporting by Wendell Roelf Editing by Alexander Winning)

© 2019 Thomson Reuters. All rights reserved. Reuters content is the intellectual property of Thomson Reuters or its third party content providers. Any copying, republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. "Reuters" and the Reuters Logo are trademarks of Thomson Reuters and its affiliated companies.